- Home
- IMMX vs DHIL Comparison
IMMX vs DHIL Comparison
Compare IMMX & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMMX | DHIL |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.9M | 319.2M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | IMMX | DHIL |
|---|---|---|
| Price | $5.67 | $169.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 50.4K |
| Earning Date | 11-07-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 17.21 |
| Revenue | N/A | ★ $149,665,296.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.79 |
| Revenue Growth | N/A | ★ 2.65 |
| 52 Week Low | $1.34 | $114.11 |
| 52 Week High | $7.73 | $171.43 |
Technical Indicators
Market Signals| Indicator | IMMX | DHIL |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 80.69 |
| Support Level | $5.33 | $168.51 |
| Resistance Level | $7.73 | $171.00 |
| Average True Range (ATR) | 0.77 | 2.00 |
| MACD | -0.07 | 5.51 |
| Stochastic Oscillator | 48.35 | 94.78 |
Price Performance
Historical ComparisonAbout IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.